7-benzyloxy-6-methoxyisatoic anhydride | 253777-45-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶嗪类
• 英文名称: 7-benzyloxy-6-methoxyisatoic anhydride
• 英文别名: 6-methoxy-7-phenylmethoxy-1H-3,1-benzoxazine-2,4-dione
• CAS: 253777-45-6
• 化学式: C₁₆H₁₃NO₅
• 分子量: 299.283
• InChiKey: LSBPSNQQDABGQU-UHFFFAOYSA-N

物化性质

• 熔点：
  232-235 °C
• 密度：
  1.329±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  73.9
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  7-benzyloxy-6-methoxyisatoic anhydride 在 camphor-10-sulfonic acid 偶氮二异丁腈 、 三正丁基氢锡 、 sodium hydride 、 potassium carbonate 、 臭氧 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 、 N,N-二甲基乙酰胺 、 水 、 乙腈 、 苯 为溶剂， 反应 18.25h， 生成 (11aS)-8-benzyloxy-7-methoxy-1,2,3,9,10,11,11a-hexahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepin-5-one
  参考文献：
  名称：

  A Novel Route to Pyrrolo[2,1-c][1,4]benzodiazepin-5-ones. Formal Total Synthesis of (±)-DC-81

  摘要：

  [GRAPHICS]Compounds 3a and 3b were synthesized from N-allylisatoic anhydrides 5a and 5b in six and seven steps, respectively, Synthesis of 3b constitutes a formal total synthesis of (+/-)-DC-81.

  DOI：

  10.1021/ol991100g
• 作为产物：
  描述：

  4-苄氧基-3-甲氧基苯甲酸 在 四氯化锡 、 nickel dichloride sodium hydroxide 、 sodium tetrahydroborate 、 硝酸 、 potassium carbonate 、 甲苯 作用下， 以 甲醇 、 sodium hydroxide 、 二氯甲烷 、 丙酮 为溶剂， 反应 6.67h， 生成 7-benzyloxy-6-methoxyisatoic anhydride
  参考文献：
  名称：

  A Novel Route to Pyrrolo[2,1-c][1,4]benzodiazepin-5-ones. Formal Total Synthesis of (±)-DC-81

  摘要：

  [GRAPHICS]Compounds 3a and 3b were synthesized from N-allylisatoic anhydrides 5a and 5b in six and seven steps, respectively, Synthesis of 3b constitutes a formal total synthesis of (+/-)-DC-81.

  DOI：

  10.1021/ol991100g

文献信息

• [EN] UNSYMMETRICAL PYRROLOBENZODIAZEPINES-DIMERS FOR USE IN THE TREATMENT OF PROLIFERATIVE AND AUTOIMMUNE DISEASES<br/>[FR] DIMÈRES DE PYRROLOBENZODIAZÉPINES ASYMÉTRIQUES À UTILISER DANS LE TRAITEMENT DE MALADIES PROLIFÉRATIVES ET AUTO-IMMUNES
  申请人：SPIROGEN SARL

  公开号：WO2014096365A1

  公开（公告）日：2014-06-26

  A compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein: R2 is of formula (IIa), formula (IIb) or formula (IIc): (a) where A is a C5-7 aryl group, and either (i) Q1 is a single bond, and Q2 is selected from a single bond and -Z-(CH2)n-, where Z is selected from a single bond, O, S and NH and n is from 1 to 3; or (ii) Q1 is -CH=CH-, and Q2 is a single bond; (b) where: RC1, RC2 and RC3 are independently selected from H and unsubstituted C1-2 alkyl; (c) where Q is selected from OH, SH and NRN, and RN is selected from H, methyl and ethyl X is selected from the group comprising: OH, SH, CO2H, COH, N=C=O, NHNH2, CONHNH2, (formula (x)), (formular (y), NHRN, wherein RN is selected from the group comprising H and C1-4 alkyl; and either: when there is a double bond present between C2' and C3', R12 is selected from the group consisting of: (ia) C5-10 aryl group, optionally substituted by one or more substituents selected from the group comprising: halo, nitro, cyano, ether, carboxy, ester, C1-7 alkyl, C3-7 heterocyclyl and bis-oxy-C1-3 alkylene; (ib) C1-5 saturated aliphatic alkyl; (ic) C3-6 saturated cycloalkyl; (id), wherein each of R21, R22 and R23 are independently selected from H, C1-3 saturated alkyl, C2-3 alkenyl, C2-3 alkynyl and cyclopropyl, where the total number of carbon atoms in the R12 group is no more than 5; (ie), wherein one of R25a and R25b is H and the other is selected from: phenyl, which phenyl is optionally substituted by a group selected from halo, methyl, methoxy; pyridyl; and thiophenyl; and (if), where R24 is selected from: H; C1-3 saturated alkyl; C2-3 alkenyl; C2-3 alkynyl; cyclopropyl; phenyl, which phenyl is optionally substituted by a group selected from halo, methyl, methoxy; pyridyl; and thiophenyl; when there is a single bond present between C2' and C3', R12 is (formula (z)), where R26a and R26b are independently selected from H, F, C1-4 saturated alkyl, C2-3 alkenyl, which alkyl and alkenyl groups are optionally substituted by a group selected from C1-4 alkyl amido and C1-4 alkyl ester; or, when one of R26a and R26b is H, the other is selected from nitrile and a C1-4 alkyl ester; R6 and R9 are independently selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR', nitro, Me3Sn and halo; where R and R' are independently selected from optionally substituted C1-12 alkyl, C3-20 heterocyclyl and C5-20 aryl groups; R7 is selected from H, R, OH, OR, SH, SR, NH2, NHR, NHRR', nitro, Me3Sn and halo; R" is a C3-12 alkylene group, which chain may be interrupted by one or more heteroatoms, e.g. O, S, NRN2 (where RN2 is H or C1-4 alkyl), and/or aromatic rings, e.g. benzene or pyridine; Y and Y' are selected from O, S, or NH; R6', R7', R9' are selected from the same groups as R6, R7 and R9 respectively; either: (A) R20 is H or Me and R21a and R21b are both H or together form =O and either: (i) R10 is H, R11a is H and R11b is OH or ORA, where RA is C1-4 alkyl; or (ii) R10 and R11b form a nitrogen-carbon double bond between the nitrogen and carbon atoms to which they are bound and R11a is H; or (iii) R10 is H, R11a is H and R11b is SOzM, where z is 2 or 3 and M is a monovalent pharmaceutically acceptable cation; or (B) R10 is H or Me and R11a and R11b are both H or together form =O and either: (i) R20 is H, R21a is H and R21b is OH or ORA, where RA is C1-4 alkyl; or (ii) R20 and R21b form a nitrogen-carbon double bond between the nitrogen and carbon atoms to which they are bound and R11a is H; or (iii) R20 is H, R21a is H and R21b is SOzM, where z is 2 or 3 and M is a monovalent pharmaceutically acceptable cation.

  公式（I）的化合物或其药学上可接受的盐或溶剂，其中：R2为公式（IIa）、公式（IIb）或公式（IIc）：（a）其中A为C5-7芳基，且Q1为单键，Q2从单键和-Z-(CH2)n-中选择，其中Z从单键、O、S和NH中选择，n为1至3；或Q1为-CH=CH-，Q2为单键；（b）其中：RC1、RC2和RC3独立选择自H和未取代的C1-2烷基；（c）其中Q从OH、SH和NRN中选择，RN从H、甲基和乙基中选择，X从包括的组中选择：OH、SH、CO2H、COH、N=C=O、NHNH2、CONHNH2、（公式（x））、（公式（y））、NHRN，其中RN从H和C1-4烷基中选择；当C2'和C3'之间存在双键时，R12从以下组中选择：（ia）C5-10芳基，可选择地由以下一种或多种取代基取代：卤素、硝基、氰基、醚、羧基、酯、C1-7烷基、C3-7杂环烷基和双氧-C1-3烷基；（ib）C1-5饱和脂肪烷基；（ic）C3-6饱和环烷基；（id），其中R21、R22和R23各自独立选择自H、C1-3饱和烷基、C2-3烯基、C2-3炔基和环丙基，其中R12基中碳原子的总数不超过5；（ie），其中R25a和R25b中的一个为H，另一个从以下选择：苯基，该苯基可选择地由卤素、甲基、甲氧基中的一种取代基取代；吡啶基；和噻吩基；和（if），其中R24从以下选择：H；C1-3饱和烷基；C2-3烯基；C2-3炔基；环丙基；苯基，该苯基可选择地由卤素、甲基、甲氧基中的一种取代基取代；吡啶基；和噻吩基；当C2'和C3'之间存在单键时，R12为（公式（z）），其中R26a和R26b各自独立选择自H、F、C1-4饱和烷基、C2-3烯基，该烷基和烯基基团可选择地由C1-4烷基酰胺和C1-4烷基酯中的一种取代；或当R26a和R26b中的一个为H时，另一个从腈和C1-4烷基酯中选择；R6和R9独立选择自H、R、OH、OR、SH、SR、NH2、NHR、NRR'、硝基、Me3Sn和卤素；其中R和R'独立选择自可选择地取代的C1-12烷基、C3-20杂环烷基和C5-20芳基；R7从H、R、OH、OR、SH、SR、NH2、NHR、NHRR'、硝基、Me3Sn和卤素中选择；R"为C3-12烷基基团，该链可由一个或多个杂原子，例如O、S、NRN2（其中RN2为H或C1-4烷基），和/或芳香环，例如苯或吡啶，中断；Y和Y'从O、S或NH中选择；R6'、R7'、R9'从R6、R7和R9中选择的相同基团中选择；要么：（A）R20为H或Me，R21a和R21b都为H或一起形成=O，且要么：（i）R10为H，R11a为H，R11b为OH或ORA，其中RA为C1-4烷基；或（ii）R10和R11b在它们结合的氮和碳原子之间形成氮-碳双键，R11a为H；或（iii）R10为H，R11a为H，R11b为SOzM，其中z为2或3，M为一价的药学上可接受的阳离子；或（B）R10为H或Me，R11a和R11b都为H或一起形成=O，且要么：（i）R20为H，R21a为H，R21b为OH或ORA，其中RA为C1-4烷基；或（ii）R20和R21b在它们结合的氮和碳原子之间形成氮-碳双键，R11a为H；或（iii）R20为H，R21a为H，R21b为SOzM，其中z为2或3，M为一价的药学上可接受的阳离子。
• Facile and Efficient Solid-Phase Synthesis of DNA-Interactive Pyrrolo[2,1-<i>c</i>][1,4]benzodiazepines
  作者：Ahmed Kamal、K. Laxma Reddy、V. Devaiah、N. Shankaraiah

  DOI：10.1055/s-2004-829096

  日期：——

  The solid-phase synthesis ofpyrrolo[2,1-c][1,4]benzodiazepines is described. Isatoic anhydrides attached to chloromethyl Wang resin are coupled with proline and the polymer-bound tricyclic compounds are reduced using verymild conditions, and successively cleaved from the resin to afford the desired imine-containing heterocyclic compounds. Reactions were monitored by FT-IR spectroscopy on the resin

  描述了吡咯并[2,1-c][1,4]苯二氮卓类的固相合成。连接到氯甲基 Wang 树脂上的芥酸酐与脯氨酸偶联，聚合物结合的三环化合物在非常温和的条件下被还原，然后从树脂上连续裂解，得到所需的含亚胺的杂环化合物。通过树脂珠上的FT-IR光谱监测反应。
• UNSYMMETRICAL PYRROLOBENZODIAZEPINES-DIMERS FOR USE IN THE TREATMENT OF PROLIFERATIVE AND AUTOIMMUNE DISEASES
  申请人：SPIROGEN SÀRL

  公开号：US20150315196A1

  公开（公告）日：2015-11-05

  A compound of formula I: or a pharmaceutically acceptable salt or solvate thereof.

  公式I的化合物：或其药学上可接受的盐或溶剂。
• An Efficient Synthesis of Pyrrolo[2,1-<i>c</i>][1,4]benzodiazepine. Synthesis of the Antibiotic DC-81
  作者：Wan-Ping Hu、Jeh-Jeng Wang、Fu-Lung Lin、Yu-Chen Lin、Shinne-Ren Lin、Mei-Hui Hsu

  DOI：10.1021/jo010043d

  日期：2001.4.1
• US9567340B2
  申请人：——

  公开号：US9567340B2

  公开（公告）日：2017-02-14